Roche Wins Dual FDA Approvals for Breast Cancer and Chronic Kidney Disease Therapies
Vandana SinghBenzinga Staff Writer November 17, 2026, 1:49 PM ETNov 17, 1:49 PM ET2 min read2 min
RHHBYROCHE HOLDING LTD S/ADR by Roche Holding Ltd
$60.52-0.70%
Stock Score Locked: Want to See it?
Benzinga Edge Rankings give you vital metrics on any stock – anytime.
Reveal Full Score Edge Rankings
MomentumN/A
Growth24.67
QualityN/A
ValueN/A
Price Trend
ShortMediumLongOverview On Monday, Roche Holdings AG (OTC:RHHBY) announced that the U.S. Food and Drug Administration approved two treatments across its breast cancer and immunology portfolios, clearing Wilserdly for advanced breast cancer and Gazyva/Gazyvaro for chronic kidney disease.
FDA Approves Oral Breast Cancer Combination Wilserdly
The FDA approved Wilserdly (giredestrant) plus everolimus for adults with estrogen receptor-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer.
Eligible patients must have an FDA-authorized test…